INTRODUCTION
Alterations of gene expression and subsequent function, whether through activation of oncogenes or suppression of tumour suppressors, are hallmark contributors to the development of malignancy. These alterations often result from chromosomal translocations or deletions of segments of the genome that result in modified gene expression or fusion of two distinct gene transcripts. Such chromosomal structural rearrangements are common in haematological malignancies and often function as exclusive trigger points in oncogenesis [1] [2] [3] . For example, the translocation of the BCR gene from chromosome 22 with the ABL gene of chromosome 9, yielding the 'Philadelphia chromosome', results in the production of a BCR-ABL fusion protein with a constitutively active tyrosine kinase domain that drives the development of chronic myeloid leukaemia. While this is an example of a chromosomal translocation resulting in fusion of two transcripts resulting in a fusion protein, structural rearrangements of the chromosome can drive the development of malignancy through many methods. These alterations can change gene products directly or inappropriately modify gene expression by associating upstream promoters or regions of epigenetic control (e.g. hypermethylation of upstream promoters) with other genes (Fig. 1) .
WHY DO FUSIONS MATTER?
The pervasive nature of structural rearrangements in haematological malignancies enables cytogenetics and fusion status to determine tumour subtyping and appropriate therapy decisions [4] . The modern era of targeted drug therapy was bolstered by the success of imitanib (Gleevec) development for targeting the tyrosine kinase domain of the BCR-ABL fusion [5] . Unfortunately, structural rearrangements are historically rare in carcinomas. Besides the obvious explanation that the rearrangements may not exist, the assumption was that chromosomal changes are difficult to discover and document in epithelial-based tumours. Carcinoma cells are difficult to culture and studies based on solid tumour samples detect many nonspecific chromosomal changes. However, recent advances in genomic profiling, through the use of microarrays, spectral karyotyping (SKY), and competitive genomic hybridization (CGH), has coupled with the emerging field of bioinformatics to uncover many findings not evident with standard analysis techniques. As an example of the power of bioinformatic analysis to detect new associations from previously analysed data, the Chinnaiyan research group developed the Cancer Outlier Profile Analysis (COPA) algorithm to analyse DNA microarray studies, which led to the identification of recurrent chromosomal rearrangements in prostate cancer [6] .
COPA ANALYSIS
COPA is based on the three theories: (i) chromosomal rearrangements and amplifications may result in marked overexpression of involved genes, (ii) such alterations are often heterogeneous in a given cancer type, and (iii) the altered gene expression in a subset of samples may be overshadowed when analysing DNA microarray studies using standard analytical approaches (e.g. a two class t -test method). Thus, COPA is designed to detect genes that have very high expression in only a subset of cancer cases, e.g. gene A is highly overexpressed in only 5% of tumour samples. While the full statistical methodology is outside the realm of this review, for every gene in a given microarray study, the median expression for all samples is centred to 0 and the median absolute deviation is set to 1. This process compresses a biomarker gene profile that has generalized overexpression in cancer compared with normal and accentuates an outlier gene profile that only has overexpression in a subset of cancer cases. As is typical for microarray analysis, the genes are then rank ordered by the extent of their 'outlier' score to enable selection of genes for further characterization and study. Applying this method to multiple cancer datasets ranks genes with known rearrangements at or near the top of the list, e.g. PBX1 ranks number one for outliers from a microarray dataset of leukaemia cases with confirmed fusion of the PBX1 gene [7] (Table 1) [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] . The results of COPA analysis of prostate cancer studies identified erythroblastosis virus E26 transforming sequence (ETS) variant gene 1 ( ETV1 ) and v-ETS erythroblastosis virus E26 oncogene like ( ERG) as outliers in a fraction of cases with COPA scores in the top 10 for six independent prostate profiling studies [6] . ETV1 (7p21.2) and ERG (21q22.3) are genes from the ETS family of transcription factors and have previously been implicated in oncogenic translocations in Ewing's sarcoma and myeloid leukaemia [18, 19] . Furthermore, ETS members are functionally redundant in cancer development, as only one ETS gene is involved in a translocation in each case of Ewing's sarcoma [19] . As further support for a role in prostate cancer oncogenesis, the overexpression of ETV1 and ERG was mutually exclusive and raised the possibility that the overexpression of these genes acts as a trigger point in cancer development.
DISCOVERY OF PROSTATE GENE FUSIONS
To determine if structural rearrangements may be responsible for the overexpression of ETV1 and ERG , the RNA from prostate cancer samples was characterized quantitatively using a PCR-based test. Real-time quantitative PCR (qPCR) determines the amount of RNA transcript for a gene of interest by amplifying a segment of the gene transcript and directly measuring the amount of transcript during the amplification process using fluorescent dyes. When applied to prostate cancer, qPCR consistently showed a loss of the 5 ′ region of ETV1 or ERG for cases with marked overexpression of the 3 ′ end. Next, RNA ligase mediated rapid amplification of cDNA ends (RLM-RACE) was used to characterize the 5 ′ end of the ERG or ETV1 transcripts in such samples. Sequencing determined that the 5 ′ end of ETV1 or ERG was consistently replaced with the 5 ′ untranslated region of the prostate specific gene transmembrane protease, serine 2 ( TMPRSS2 ; 21q22.2) (Fig. 2) . After documenting the fusion of TMPRSS2 to ETV1 or ERG in cases with overexpression, qPCR using forward primers in TMPRSS2 and reverse primers in ETV1 or ERG was performed to confirm the fusion in a separate group of clinically localized prostate cancer samples. Once again, the overexpression of ETV1 or ERG was mutually exclusive and fusion transcripts could be detected in 95% of cases with overexpression of ETV1 or ERG , but not in benign prostate tissue samples or prostate cancers without ETV1 or ERG overexpression.
CONFIRMATION OF TRANSLOCATIONS
The detection and validation of chromosomal alterations producing gene fusions are typically based on two technologies: the use of PCR-based assays to detect and quantify gene expression and fusion transcripts, and the use of fluorescent in situ hybridization (FISH) based assays to visualize the chromosomal alteration at the genomic level. Similar to designing primers to amplify the gene transcript, FISH probes are selected from genomic DNA sequences that span or abut the segment of genomic DNA potentially involved in a translocation. For example, for FISH- Since the initial description of ETS-familymember gene fusions in prostate cancer, the results have been confirmed through many independent centres internationally (Table 2 ) [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] . As more cases are screened and identified, the exact proportion of cases with any specific fusion changes. However, with a total of > 500 samples studied, multiple groups have confirmed the largest proportion of fusions involve TMPRSS2 : ERG ( ≈ 50%), with a smaller proportion of TMPRSS2 : ETV1 (1-10%) [20] [21] [22] . As characterization continues additional ETS genes have been identified in rearrangements, such as TMPRSS2 :ETV4, and recently a family of 5 ′ partners, including SLC45A3 , HERVK_22q11.3 , HNRPA2B1 and C15ORF21 , have been identified in ETS fusions (Fig. 2) [23, 35] .
FUSION FUNCTION AS ONCOGENES?
While fusions have thus far been described in most prostate cancers, the influence of fusion status on the development of cancer remains subject to study and debate. The TMPRSS2 genes itself is prostate tissue specific and is expressed in both normal and cancerous prostate epithelium. Importantly, the expression of TMPRSS2 is induced by androgen stimulation in androgen-sensitive prostate cancer cell lines [36, 37] . [40] . As these 5′ partners are differentially regulated by androgen as described below (androgeninduced, androgen-repressed and androgeninsensitive), they define distinct classes of ETS gene rearrangements. Thus, as a prospective method of classifying ETS member fusions, our laboratory has suggested a classification schema based on the 5′ partner for ETS members (Fig. 3) . Characterizing prostate cancer cell lines with ETV1 rearrangements, we found that through distinct mechanisms, the entire ETV1 locus is rearranged to a 1.5-megabase prostatespecific region at 14q13.3-14q21.1 in both LNCaP cells (cryptic insertion) and MDA-PCa 2B cells (balanced translocation). Thus, rearrangement of the entire ETS gene into a prostate-specific-region defines Class V rearrangements [40] .
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ASSOCIATION WITH OUTCOMES
Recently, the influence of fusion status on cancer outcome has begun to be addressed. Conflicting data supports the association of TMPRSS2:ERG fusion with both improved and worsened patient outcomes. The limitations of small cohort size and varied populations are partially responsible for these findings, and have led to the lack of consensus about whether gene fusions influence the risk of prostate cancer progression or recurrence. Initial screening studies seeking to determine the proportion of cases with gene fusion found no association with PSA recurrence [20, 23] . Many of these studies were unable to determine the association with PSA recurrence due to limitations in follow-up and instead reported the association with assumed surrogates of cancer risk such as disease stage and Gleason grade. While some studies have shown correlation with higher stage disease [20] , others report either no association with Gleason score [23, 39] or an association with lower Gleason score and better survival [22] . On the other hand, a surgical series of 59 patients including 34 cases with PSA recurrence and advanced pathological stage, recently reported an association between certain isoforms of fusion with early recurrence and seminal vesicle invasion [24] . The number of exons from TMPRSS2 and the alignment of TMPRSS2 with downstream ERG exons determined up to eight isoforms, including the two initially described by Tomlins et al. [6] and had a significant impact on disease characteristics. In a separate surgical series of 26 patients including 11 (42%) with TMPRSS2:ERG fusion, patients with fusion had a higher rate of biochemical recurrence (80%) than did fusion negative patients (38%) [29] . Additionally, TMPRSS2:ERG fusion was significantly associated with a higher likelihood of prostate cancer-specific death in a cohort of 111 men in a watchful-waiting cohort [25] . Although TMPRSS2:ERG fusion may be associated with lower disease survival in a European watchful-waiting cohort, the patient population from this cohort differs from the patient cohorts identified through PSA-screening in the USA [20] . The overall proportion of cases with gene fusion is much lower, only 15%, than the proportion noted in screening populations in the USA of >50%, and therefore caution should be used before extrapolating the study conclusions to a population with a different fusion penetrance. Furthermore, these trials reflect small cohorts when compared with the thousands of patients presenting for prostate cancer treatment and results should be confirmed on larger, more inclusive cohorts before fusion status can be utilized to risk stratify patients with prostate cancer.
FUTURE APPLICATIONS
Gene fusion status may eventually be used for pretreatment risk stratification, for enrolment in active surveillance trials, or for guidance during surveillance after therapy. Given the protracted course of prostate cancer progression, supporting data from prospective trials may take years to accumulate. However, due to the specificity of gene fusions for prostate cancer compared with normal, PIA, or BPH nodules, fusion status is currently being developed as a biomarker for prostate cancer presence [39] . 
